DECLARE-TIMI 58 (Dapagliflozin Effect on Cardiovascular Events– Thrombolysis in Myocardial Infarction 58) studied the safety and efficacy of dapagliflozin [a sodium-glucose cotransporter (SGLT2) inhibitor] vs. placebo in 17,160 type 2 diabetes mellitus patients with either multiple risk factors for atherosclerotic cardiovascular disease (n = 10,186) or known atherosclerotic cardiovascular disease (n = 6,974). Here, SLC5A2 is linked to type 2 diabetes mellitus.